JCO9 Rec'd PCT/PTO 23 SEP 2005

Attorney Docket No. Le A 36 571

PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Fischer, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/002580

Title: Benzofuro-1,4-Diazepin-2-One Derivatives

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

### IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

#### **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino Reg. No.: 48.972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-

Facsimile: (203) 812-6459

### JC09 Rec'd PCT/PTO 23. SEP. 2005

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	[to be assigned]	
IA	IEODMAT:	ON DIE	CLOSURE	Filing Date		
		<del>-</del>		First Named Inventor	Rüdiger Fischer	
S	TATEMEN	IT BY AF	PPLICANT	Art Unit		
	(Use as ma	ny sheets as ne	cessary)	Examiner Name		
Sheet	1 1	of	2	Attorney Docket Number	Le A 36 571	

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	<u> </u>	Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
		US-			

Examiner	Cite	Foreign Patent Document	IGN PATENT DOCL		Danie Ostrono Harr	
Initials*	No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	140.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of often bocument	Or Relevant Figures Appear	Τ'
	F1	EP 0 350 131	01/10/1990	Duphar Intern. Research B.V.		
	F2	WO 01/51490	07/19/2001	U.S. Dept. Health & Human Serv.		

Examiner		Date	
Signature		Considered	
Oignaturo .		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Tris collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/551296

## JC09 Rec'd PCT/PTO 23 SEP 2005

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO				Complete if Known		
				Application Number	[to be assigned]	
INFO	ORMATION	N DIS	CLOSURE	Filing Date		
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	Rüdiger Fischer	
	// too oo	4		Art Unit		
	(Use as many sh	eets as n	ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	Le A 36 571	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	Т
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	[Database Chemcats Online] Chemical Abstracts Service, Columbus, OH, US XP002286040 Order No. STOCK3S-12084, Accession No. 2003:2381771, Interbioscreen Compound Library, 09 May 2003, Interbioscreen Ltd., Moscow, Russia.	
	R2	[Database Chemcats Online] Chemical Abstracts Service, Columbus, OH, US XP002286041 Order No. STOCK1N-32008, Accession No. 2003:2367960, Interbioscreen Compound Library, 09 May 2003, Interbioscreen Ltd., Moscow, Russia.	
	R3	MILLER, et al., "Cibacron Blue Allosterically Modulates the Rat P2X4 Receptor," Neuropharmacology, 37 (12): 1579-1586 (1998).	
	R4	[Database Beilstein] Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE XP002286042 Database Accession No. 6561550, "Cibacron Blue" & J. Phys. Chem., 87(8): 1329-1337 (1983).	
	R5	[Database Beilstein] Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE XP002286043 Database Accession No. 8185304, "Pharmacological Data" & Mol. Pharmacol., 48(1): 178-183 (1995).	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.